Despite market uncertainty, healthcare CEOs of all stripes remain upbeat about 2019
The market gyrations, the shutdown, the trade war, the Texas judge - nothing can get these four healthcare CEOs down as they look at 2019.
The market gyrations, the shutdown, the trade war, the Texas judge - nothing can get these four healthcare CEOs down as they look at 2019.
Members of the press don't pay to attend the annual J.P. Morgan Healthcare Conference, which has been traditionally a must-attend event for many healthcare professionals, but the value even for us is rapidly dwindling.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The agency plans to release several guidances on complex generics and biosimilars, along with taking a deep dive into the Orange Book patent and exclusivity database.
Lack of innovation has contributed to the industry’s failure to drive down the cost curve and regardless of how Amazon/Berkshire/JP Morgan moves forward, other large employers will be anxious to leverage any programs that successfully lower costs.
The J.P. Morgan Healthcare Conference is about so much more than the company presentations. Partnerships are made, deals are signed, and the tone for the biopharma year ahead is set. Or is it?